The stock of Retrophin Inc (NASDAQ:RTRX) is a huge mover today! The stock increased 3.31% or $0.74 during the last trading session, hitting $23.12. About 413,795 shares traded hands. Retrophin Inc (NASDAQ:RTRX) has risen 57.27% since February 29, 2016 and is uptrending. It has outperformed by 45.06% the S&P500.
The move comes after 9 months positive chart setup for the $868.63 million company. It was reported on Oct, 4 by Barchart.com. We have $35.14 PT which if reached, will make NASDAQ:RTRX worth $451.69 million more.
Analysts await Retrophin Inc (NASDAQ:RTRX) to report earnings on November, 1. They expect $-0.24 earnings per share, down 50.00% or $0.08 from last year’s $-0.16 per share. After $-0.08 actual earnings per share reported by Retrophin Inc for the previous quarter, Wall Street now forecasts 200.00% negative EPS growth.
Retrophin Inc (NASDAQ:RTRX) Ratings Coverage
Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated the stock with “Outperform” rating in Tuesday, April 12 report. The rating was initiated by JMP Securities on Monday, November 2 with “Mkt Outperform”. The rating was downgraded by Zacks on Wednesday, August 12 to “Buy”.
According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include ChenodalÂ®, Cholbam, and ThiolaÂ®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”
Insitutional Activity: The institutional sentiment increased to 1.3 in Q2 2016. Its up 0.23, from 1.07 in 2016Q1. The ratio is positive, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.
Moreover, Nationwide Fund has 0% invested in Retrophin Inc (NASDAQ:RTRX) for 23,344 shares. Aqr Cap Mgmt Limited reported 86,775 shares or 0% of all its holdings. Bogle Invest L P De, a Massachusetts-based fund reported 20,543 shares. Schwab Charles Inv owns 120,921 shares or 0% of their US portfolio. The Pennsylvania-based Pnc Services Gp Inc has invested 0% in Retrophin Inc (NASDAQ:RTRX). First Mercantile Trust accumulated 5,930 shares or 0.01% of the stock. Blackrock Japan holds 0% or 443 shares in its portfolio. Public Employees Retirement Association Of Colorado last reported 10,796 shares in the company. Fincl Bank Of America De holds 21,524 shares or 0% of its portfolio. Macquarie Gp Ltd holds 929,316 shares or 0.03% of its portfolio. Tekla Cap Ltd Limited Liability Company holds 0.24% of its portfolio in Retrophin Inc (NASDAQ:RTRX) for 329,949 shares. Consonance Capital Mgmt L P holds 6.81% or 2.70M shares in its portfolio. California State Teachers Retirement Systems, a California-based fund reported 75,938 shares. Lombard Odier Asset Mngmt (Usa) last reported 2.34% of its portfolio in the stock. Oxford Asset Mngmt last reported 0.16% of its portfolio in the stock.
Insider Transactions: Since June 1, 2016, the stock had 0 buys, and 2 insider sales for $297,343 net activity. Shares for $155,284 were sold by Shih Alvin on Wednesday, June 1.
More important recent Retrophin Inc (NASDAQ:RTRX) news were published by: Fool.com which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016, also Fool.com published article titled: “Why Retrophin Inc was Down Today”, Reuters.com published: “Retrophin to pay $3 million in US lawsuit over Shkreli’s tenure” on February 03, 2016. More interesting news about Retrophin Inc (NASDAQ:RTRX) was released by: Seekingalpha.com and their article: “Retrophin Is A Strong Buy On Positive Sparsentan Results” with publication date: September 12, 2016.
RTRX Company Profile
Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.